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Abstract
Background: Behavioural and psychological symptoms of dementia (BPSD) are non-cognitive symptoms
commonly associated to Alzheimer’s disease (AD). The characterization of the clinical profile of AD patients might
help to better understand disease evolution and to improve diagnosis and treatment. Thus, the aim of the present
study is to describe the clinical profile of AD patients, and to correlate the presence of BPSD with the severity of
the disease.
Methods: A cross-sectional, observational and multicenter study was conducted at 115 centres in Spain. Patients
suffering from AD with higher and lower BPSD scores (ADAS-Noncog score 26-50 and ≤25, respectively) were
included. Demographic and clinical data were collected, and dementia severity was assessed by the Mini Mental
State Examination (MMSE) [mild 27-21, moderate 20-11, severe ≤10]. The use of ADAS-Noncog in clinical practice
was also explored.
Results: A total of 1014 patients (463 with higher and 551 with lower BPSD scores) were included (mean age 77 ± 7
years, 65% women). Almost all patients (90%) had BPSD at inclusion, 17% of which reported psychotic outbreaks.
The most prevalent symptoms were lack of concentration (56%), tremors (56%), depression (44%), lack of
cooperation (36%), and delusions (32%). Patients with higher BPSD scores showed a significantly higher
prevalence of psychotic symptoms (delusions, hallucinations, and delirium) and tremors, while emotional
symptoms (tearfulness and apathy) predominated in patients with lower BPSD scores. MMSE and ADAS-Noncog
scores were negatively associated (p = 0.0284), suggesting a correlation between cognitive impairment and
BPSD. Lack of concentration and appetite change significantly correlated with MMSE (p = 0.0472 and p =
0.0346, respectively). Rivastigmine and donepezil were the first choice therapies in mild to moderate dementia.
ADAS-Noncog was generally considered better or similar to other scales (82%), and 68% of the investigators
were willing to use it in the future.
Conclusions: Our study shows that patients with AD have a high prevalence of noncognitive symptoms, and that
cognitive impairment and BPSD are correlated. Therefore, ADAS-Noncog is a useful evaluation tool.
Background
Dementias, and particularly Alzheimer’sd i s e a s e( A D ) ,
are a growing public health problem that results from
population ageing [1]. The hallmarks of dementia are
functional, cognitive, and behavioural manifestations.
Among the first manifestations of dementing disorders
are behavioural symptoms which might appear before cog-
nitive alterations [2], at some time during the course of the
illness [2,3] and vary according to dementia severity [4].
Behavioural and psychological symptoms of dementia
(BPSD) are non-cognitive symptoms commonly asso-
ciated to AD. Early detection of BPSD is extremely
important, because these symptoms not only induce
noticeable disability in demented patients, but also
increase the caregiver stress [5]. In fact, BPSD increase
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nitive decline [8] and worsen patient’s quality of life [9].
Besides, behavioural disturbances represent the main
reason for and lead to early patient institutionalization
[10,11], increasing the overall financial cost [12]. How-
ever, when correctly diagnosed, these disorders can be
efficiently treated with drugs [13,14] and, therefore,
delay nursing home placement and improve patients’
and caregivers’ quality of life.
Several studies have been conducted to assess the pre-
valence of BPSD symptoms, so depending on the type
of population studied and on the methods used to
assessed it, the prevalence ranges from 61% to 92%
[15-18]. Since the frequency of BPSD is highly variable,
the correct assessment of these symptoms may contri-
bute to a better diagnosis and treatment, and could be
a powerful tool to evaluate the efficacy of any therapy
directed towards the improvement of behavioural
disturbances.
Currently, BPSD can be assessed by standardized
instruments such as the Neuropsychiatric Inventory
(NPI) [15,18,19], the Behaviour Pathology in Alzheimer’s
Disease (BEHAVE-AD) scale [20], and the Alzheimer’s
Disease Assessment Scale (ADAS) [21,22]. The ADAS,
and especially its non-cognitive subscale (ADAS-
Noncog), is a specific diagnostic tool designed to
detect BPSD in patients with AD. An adapted and
validated Spanish version of this rating scale is also
available [23,24].
A cross-sectional and multicenter study has been con-
ducted with the aim of describing the BPSD and the
clinical profile (age, gender, severity of dementia) of AD
patients showing lower and higher behavioural symp-
toms, according to the ADAS-Noncog scale. In addition,
the relationship between BPSD and cognitive impair-
ment severity of was assessed.
Secondary endpoints were to describe extrapiramydal
symptoms in AD patients, to compare Mini Mental
State Examination (MMSE) scores in patients with
higher and lower BPSD, to analyse the relationship
between MMSE scores and BPSD, and to describe the
different behavioural syndromes observed in different
subsets of patients.
Methods
Study design and conduct
A cross-sectional, observational, and multicenter study
was conducted at 115 neurology centres in Spain. The
study was approved by the Clinical Ethics Committee
of the Hospital de Cruces (Bilbao), and all patients or
their legal representatives provided written informed
consent. The study was in accordance with the Helsinki
Declaration principles for medical research involving
human subjects.
Patient population
Patients with diagnosis of AD according to DSM-IV cri-
teria and with available clinical data from the previous
year were eligible for the study. During five months,
each physician recruited five to six patients with higher
BPSD scores and five to six patients with lower BPSD
scores. Patients in the first group had ADAS-Noncog
total scores ranging from 26-50 and patients in the
lower group had scores ≤25. The ADAS-Noncog is a
validated 10-item tool that examines aspects of mood
(tearfulness and depression) and behaviour (lack of con-
centration, lack of cooperation, delusions, hallucinations,
pacing, motor behaviour, tremors, and appetite change).
Each item is rated on a 5-point scale; thus, total scores
range from 0 to 50. Higher scores represent greater
mood or behavioural disturbances. Ratings were made
by the examiner based on the information obtained
from patients, family members or caregivers, and profes-
sional observations.
At the selection visit, in addition to ADAS-Noncog
test, MMSE test was performed and the presence or
absence of BPSD during the last year was reported.
Variables
The main outcome of the study was the ADAS-Noncog
score obtained at baseline. The main variable of the
study was dementia severity which was categorized into
three categories: mild (27-21), moderate (20-11) and
severe (≤10) according to MMSE scores.
Secondary variables included demographic data, years
since AD diagnosis, pharmacological treatments for AD/
BPSD in the last year, concomitant diseases and treat-
ments, presence of psychotic breaks and extrapyramidal
symptoms (tremors, rigidity, hypokinesia, postural
instability, and fluctuating cognition) during the last
year, and the description of the most frequent BPSD at
inclusion and during the previous year (possible symp-
toms included ADAS-Noncog items and some BPSD of
the International Psychogeriatric Association [25], such
as apathy, anxiety, agitation, and delirium). Finally, phy-
sicians were asked about their use of the ADAS-Noncog
scale in clinical practice.
Statistics
Sample size calculation was based on the description
of dementia severity and was calculated using NCSS
2004 and PASS 2002 softwares. A minimum of 507
patients per BPSD group were required to obtain a
precision of 4.5% for each dementia degree with a
95% confidence interval (95%CI), assuming a 10% of
patient losses.
All statistical analyses were made with the SAS 8.2
software using a two-tailed alpha level of 0.05. Data are
presented as percentages for discrete variables, and as
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between groups were assessed using the Chi-square test
for categorical data and using one-way ANOVA (or
Mann-Whitney test when data was not normally distrib-
uted) for continuous variables. Finally, the association
between continuous variables was tested by using the
Spearman correlation coeficient. The strength of the
association was regarded as very weak for Spearman
coefficient values of 0-0.19, as weak for 0.2-0.39 values,
as moderate for 0.40-0.59 values, as strong for 0.6-0.79
values, and as very strong for 0.8-1 values. Principal
component analysis was used for factor analysis of the
ADAS-Noncog. Factors were selected on the basis of
eigenvalue-one criterion and varimax (orthogonal) rota-
tion was applied.
Results
Population description
A total of 1014 patients were included in the study, 463
of them were in the higher BPSD group and the remain-
ing were in with the lower BPSD group. One hundred
and sixty-one additional subjects were excluded from the
analysis due to absence of ADAS-Noncog score and/or
not meet inclusion criteria. The mean ADAS-Noncog
score in the in the higher BPSD group was 29.8 ± 3.4,
indicating a moderate degree of behavioural symptoms.
Patients in the lower BPSD group showed an average
score of 10.4 ± 6.4. A summary of the most relevant
characteristics of the studied population are presented
in Table 1.
The mean age of the overall sample was 77.2 ± 6.8
years old, and 65% were women (Table 1). Half of the
patients (51%) had no primary education, whereas 37%
of them completed primary school, 9% secondary educa-
tion, and 3% had a university degree. Since most
patients (85%) were living at their home, the caregiver
was usually a family member, especially a son or daugh-
ter (54%) or the spouse (39%). Only the 3% of caregivers
were paid medical professionals.
As described in Table 1, 90% of patients had shown
behavioural symptoms during the previous year. The
most common were lack of cooperation and depression,
with prevalence above 50%. It is noteworthy that these
symptoms had been underdiagnosed, since only 41% of
the studied population hadp r i o rd i a g n o s i so fB P S D .
Likewise, more than half of the patients (54%) had
experienced extrapyramidal symptoms, predominantly
tremors (38%) and rigidity (14%). Psychotic breaks
occurred to 17% of patients, with an average of 2.1 ±
2.7 breaks.
On the basis of the MMSE score, dementia severity
was usually mild (39%) to moderate (47%). Only the
14% of the patients had severe dementia (Table 1).
Clinical profile according to the scores BPSD
According to the results described in Table 1, no signifi-
cant differences were observed between both groups of
patients regarding age, gender, duration of AD, and
treatment. The occurrence of BPSD, extrapyramidal
symptoms, and psychotic breaks, during the previous
year was also comparable between groups.
At inclusion time, almost all patients showed some
behavioural symptoms (92%). The most prevalent were:
lack of concentration (56%), tremors (56%), depression
(44%), lack of cooperation (36%), delusions (32%), motor
behaviour (29%), and tearfulness (28%) (Table 2).
Table 1 Demographic and clinical history data of patients
with AD with higher (N = 463) and lower BPSD scores
(N = 551)
AD + BPSD AD - BPSD
Age (mean ± SD) 77.3 ± 6.7 77.1 ± 6.9
Gender (% men) 35.4% 34.8%
Years since AD symptoms (mean ± SD) 3.87 ± 2.32 3.89 ± 2.50
Years since AD diagnosis (mean ± SD) 1.32 ± 1.33 1.26 ± 1.19
Prior diagnosis of BPSD (before1 year) 42.7% 39.1%
Current treatment for AD 94.8% 95.6%
Behavioural symptoms (last year) 89.8% 89.7%
Tearfulness 36.1% 40.8%
Depression 49.9% 51.9%
Concentration 59.0% 59.7%
Cooperation 40.0% 42.5%
Delusions 42.1% 37.0%
Hallucinations 32.8% 28.5%
Pacing 31.5% 26.5%
Motor activity 35.2% 33.8%
Appetite change 29.8% 29.6%
Apathy 23.8% 24.0%
Anxiety 27.6% 24.5%
Agitation 25.5% 24.1%
Delirium 8.9% 6.9%
Extrapyramidal symptoms (last year) 53.8% 54.6%
Tremors 37.6% 38.3%
Rigidity 14.0% 14.3%
Hypokinesia 11.2% 9.8%
Postural instability 9.9% 8.3%
Fluctuating cognition 8.6% 7.6%
Psychotic breaks (last year) 18.4% 16.0%
N° breaks (mean ± SD) 2.43 ± 3.58 1.74 ± 1.68
Dementia severity: MMSE Severe 12.8% 15.1%
Moderate 46.5% 46.6%
Mild 40.7% 38.3%
AD + BPSD: patients with higher ADAS-Noncog scores. AD - BPSD: patients
with lower ADAS-Noncog scores.
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terize the patients in the higher BPSD group were psy-
chotic, such as delusions (p = 0.0417), hallucinations
(p = 0.0451), delirium (p = 0.0233), and tremors (p <
0.001). Among patients in the lower BPSD group, the
most prevalent were emotional symptoms such as tear-
ful mood (p = 0.0170) and apathy (p = 0.0310). The
frequencies of all BPSD between groups at inclusion are
compared in Table 2.
Regarding dementia severity, there were no significant
differences in MMSE score between both groups
(p > 0.05).
Correlation between the presence of BPSD and dementia
severity
A significant negative association was observed between
dementia severity (MMSE score) and ADAS-Noncog
score (p = 0.0284) in patients in the higher BPSD group,
indicating that BPSD symptoms got worse when cogni-
tion decreased. Specifically, the behavioural symptoms
which showed significant associations with MMSE were
lack of cooperation (p = 0.0472) and appetite change
(p = 0.0346). In regard to, lack of concentration only a
tendency was observed (p = 0.0580). Detailed results of
correlation analyses are provided in Table 3.
Alzheimer’s disease treatment
Almost all the evaluated patients (94%) were treated
with antidementia drugs: rivastigmine (47%), donepezil
(24%), or memantine (23%) as mono or combined ther-
apy for the previous year. Besides, 37% of patients took
antipsychotic drugs, mostly risperidone (21%). Patients
with extrapyramidal symptoms received significantly
more risperidone (15%) than patients without extrapyra-
midal symptoms (6%) [p < 0.001].
When treatments were stratified by disease severity,
rivastigmine and donepezil were the first choice thera-
pies among patients showing either mild or moderate
dementia, while memantine was the most prescribed
drug in patients with severe AD. In contrast, no signifi-
cant differences in the use of cholinesterase inhibitors
and memantine were found in regard to the presence of
BPSD or extrapyramidal symptoms.
Use of ADAS-Noncog in clinical practice
In physician’s opinion, ADAS-Noncog was generally con-
sidered better than (47%) or similar to (35%) other scales.
An important percentage of the investigators regularly
used an instrument for assessing BPSD (65%). Among the
tools used to assess BPSD stood out the NPI (50%) and
the ADAS-Noncog scale (28%), whereas other scales, such
as BEHAVE-AD, Caretaker Obstreperous-Behaviour
Rating Assessment (COBRA), or Blessed Dementia Scale
(BDS), were used by less than 2% of physicians. Finally,
among the physicians who were willing to use the ADAS-
Noncog in the future (68%), 97% were already using it
(Spearman’s correlation, p < 0.0001).
Table 2 Description of current behavioural symptoms in
patients with AD with higher (N = 463) and lower BPSD
scores (N = 551)
AD + BPSD AD - BPSD
Behavioural symptoms (at inclusion) 92.2% 91.7%
Tearfulness 24.6% 31.4%*
Depression 44.5% 43.6%
Concentration 56.4% 55.4%
Cooperation 34.6% 37.0%
Delusions 35.2% 29.2%*
Hallucinations 27.0% 21.6%*
Pacing 26.6% 21.4%
Motor activity 29.4% 27.9%
Tremors 80.6% 34.2%***
Appetite change 28.5% 24.3%
Apathy 17.1% 22.5%*
Anxiety 20.3% 17.4%
Agitation 15.3% 18.3%
Delirium 4.8% 2.2%*
AD: Alzheimer’s disease; BPSD: Behavioural and psychological symptoms of
disease; AD + BPSD: patients with higher ADAS-Noncog scores. AD - BPSD:
patients with lower ADAS-Noncog scores; Chi-square test: *p < 0.05; ***p < 0.001.
Table 3 Description of current behavioural symptoms in
patients with AD with higher (N = 463) and lower BPSD
scores (N = 551)
Correlation between dementia severity (MMSE) and ADAS-Noncog
score
Present MMSE score
Spearman correlation coefficient P-value
Total ADAS-Noncog score -0.10168 0.0284
Correlation between ADAS-Noncog items and dementia severity
(MMSE)
Present MMSE score
Spearman correlation coefficient P-value
Tearfulness 0.04663 0.3167
Depression 0.01318 0.7775
Concentration -0.08797 0.0580
Cooperation -0.09210 0.0472
Delusions -0.01221 0.7928
Hallucinations -0.04601 0.3237
Pacing -0.05000 0.2841
Motor activity -0.04709 0.3115
Tremors -0.02424 0.6037
Appetite change -0.09822 0.0346
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The results of the factor analysis in both, patients with
the lower and the higher BPSD scores are shown in
Tables 4 and 5. The ten BPSD symptoms were explained
by three and four factors, for the lower and the higher
BPSD groups, respectively.
In patients with the lower BPSD scores, three factors
explained 56% of the data total variance. The first factor,
which explained 31% of total variance, denoted a dimen-
sion representing hyperactivity and had the highest load-
ings on pacing and motor activity. The second factor,
which explained 14% of total variance, represented an
affective dimension and had the highest amount on tear-
fulness and depression. The third factor, which explained
12% of the total variance, represented a psychosis dimen-
sion and had the highest degree on hallucinations and
delusions.
In patients with the higher BPSD scores, a new
dimension was added to the three mentioned above.
The four factors explained 66% of the data total variance
in the data. The first factor, which explained 22% of the
total variance, represented a hyperactivity dimension
with the highest loadings on pacing and motor activity.
The second factor, which explained18% of the total var-
iance, represented a psychosis dimension and had the
h i g h e s ta m o u n to nh a l l u c i n a t i o n sa n dd e l u s i o n s .T h e
third factor, which explained 14% of the total variance,
represented an affective dimension and had the highest
degree on tearfulness and depression. Finally, the fourth
factor, which explained 12% of the total variance,
denoted a dimension represented by lack of concentra-
tion and cooperation.
Discussion
ADAS-Noncog is a diagnostic tool especially suitable in
outpatient clinics because it does not need a special
training and its use requires a short time. In fact, its
simplicity could be the main reason for the high propor-
tion (68%) of participating physicians who reported will-
ingness to use it in the future.
An additional advantage of ADAS-Noncog Scale lies
in the interview-based assessment of the behavioural
symptoms. In contrast, other scales exclusively based on
patient relatives or caregiver’s reports may distort symp-
toms, which could be objectively analyzed by clinicians.
The results obtained in the present study are consis-
tent with other published investigations which demon-
strate that lack of concentration, tremors, depression,
lack of cooperation, and psychotic symptoms, are fre-
quent in AD patients [26-30].
In our patient series, 90% of the overall population
showed at least one BPSD in the previous year, and 92%
at the time of the initial evaluation. Similarly, another
study based on ADAS-Noncog scale [28] reported that
97% of all patients had some behavioural symptoms at
admittance.
Acording to our results, the most frequent BPSD was
lack of concentration and tremors with prevalence
around 56%. Similar results were obtain by Marin and
colleagues when studying non-cognitive disturbances in
AD [28]. Concentration alterations and lack of attention
appear very early in AD patients [31], probably due to
the bilateral tempo-parietal degeneration associated to
this disease [32]. Aside from its high prevalence, con-
centration decrease tends to be positively correlated
with cognitive impairment, suggesting that this symptom
should be considered a central deficit in AD. Tremor, in
its different manifestations, is common among elderly
population aged over 65 [33-35]. In our work, tremor
was one of the behavioural symptoms that best differen-
tiated between patients with higher and lower BPSD
scores. In that regard, patients in the higher BPSD group
had higher prevalences of delusions, hallucinations and
Table 4 Factor analysis of the ADAS-Noncong in patients
with AD with lower BPSD scores (N = 551)
Factor analysis in patients with lower BPSD
Factor 1 Factor 2 Factor 3
Tearfulness 0.02642 0.83697 0.10166
Depression 0.13897 0.82174 0.06316
Concentration 0.53240 0.33285 0.15738
Cooperation 0.59021 0.18935 0.17487
Delusions 0.15631 0.13834 0.82285
Hallucinations 0.09756 0.00094 0.84430
Pacing 0.75853 0.03146 0.23335
Motor activity 0.79410 0.00864 0.23449
Tremors 0.52143 0.04723 -0.14602
Appetite change 0.39204 0.39735 -0.07791
Italics indicate highest factor loadings.
Table 5 Factor analysis of the ADAS-Noncong in patients
with AD with higher BPSD scores (N = 463)
Factor analysis in patients with higher BPSD
Factor 1 Factor 2 Factor 3 Factor 4
Tearfulness -0.16880 -0.12826 0.76502 -0.05303
Depression -0.23948 -0.11968 0.80061 -0.02236
Concentration 0.06765 -0.09714 0.01880 0.85541
Cooperation -0.01898 -0.03624 -0.08582 0.85437
Delusions -0.05105 0.77250 -0.16114 -0.04323
Hallucinations -0.10889 0.76703 -0.22915 -0.08983
Pacing 0.86097 -0.02711 -0.17152 0.01532
Motor activity 0.86506 -0.02129 -0.17001 0.03530
Tremors -0.32619 -0.34570 -0.34536 -0.30184
Appetite change -0.20893 -0.53308 -0.36340 0.04134
Italics indicate highest factor loadings.
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and these ones would in turn induce or worsen
tremors.
Among BPSD symptoms depression is also common
in AD patients, and strongly correlates with tearful
mood. In fact, in our study, depression occupied the
third position with a prevalence of 44%. These results
are in accordance with those obtained in previous stu-
dies [28,36-38]. However, depression frequencies are
variable [39,15]. Although the relationship between
dementia and depression is controversial, the latter con-
stitutes an independent risk factor for AD [40]. Depres-
sive symptoms are frequent among patients with AD in
absence of major depression [41]. Similarly to ours,
other studies did not found correlation between cogni-
tive impairment and depression [42], indicating that the
onset of depression might occur at any stage of the
disease.
Lack of cooperation, which is generally related to an
increased motor behaviour, may be a consequence of
the normal course of disease. As for our results, the lack
of cooperation is low correlated with the degree of cog-
nitive impairment (MMSE score). However, its preva-
lence in our sample (36%) points out its relevance
among noncognitive symptoms.
The proportion of patients showing increased motor
activity or pacing (29% and 24%, respectively) is compar-
able to the one obtained in other studies [28,43]. Pacing
is especially annoying to caregivers [44] and, depending
on the population series, its occurrence range from 10%
to 60% in AD patients [29,43,45,46]. Aberrant motor
behaviour, which can lead to psychomotor agitation, is
frequent in patients with AD [29], and represents the 38
out of 100 patients [19]. In our study, agitation reached a
prevalence of 17%. Agitation may indicate a frontal affec-
tation and has a deep impact in caregivers [47].
Psychotic symptoms of AD, including delusions and
hallucinations, significantly contribute to characterize
those patients in the higher BPSD group, probably
because the increased severity of disease. Although pre-
vious studies demonstrate the relationship between
delusions and hallucinations and the degree of cognitive
impairment [48], no correlation was found in the
present study. Both symptoms are predictors of an
increased functional and cognitive decline. Moreover,
hallucinations have been associated with a higher per-
centage of institutionalization and mortality [49]. In a
cross-sectional study which included patients with AD,
vascular dementia, and dementia with Lewy bodies
(DLB), the presence of delusions and hallucinations
were related to a higher agitation and aggressiveness
[50]. Conversely, other studies failed to find any signifi-
cant correlation [19].
Among behavioural symptoms, appetite change exhib-
ited mild, although significant, negative correlation with
dementia severity. Anorexia, hyperphagia, and dietary
changes are some of the of the appetite disorders occur-
ring in AD [5,44,46]. However, hypophagia is the most
frequent alimentary disturbance in these patients. A pre-
vious study [51] demonstrated higher frequency and
severity of BSPD in patients with AD who lost weight.
Several hypotheses, such as medial temporal cortex atro-
phy, have been postulated to explain the hypophagia and
weight loss observed in these patients [52].
T h ep r e v a l e n c eo fa p a t h y( 2 0 % )i ss i m i l a rt ot h a t
reported in the literature [15]. Apathy is common
among patients with AD, and has an early onset in the
course of the disease [3,29,53]. A comparative study
including patients with AD, patients with depression,
and healthy subjects, showed that apathy may be found
isolated or coexist with depression, but it does not
increase depression scores [26].
Anxiety, involves the 19% of the studied patients. It
predominates during the initial phases of the disease,
when patients become aware of their deficit [54]. Accord-
ing to various studies, the frequency of anxiety in patients
with AD ranges from 40% to 60% [19,55]. However, only
5% to 6% of the affected patients fulfil DSM-IV criteria
for generalized anxiety disorder diagnosis [56].
In our patient population, a low significant association
between dementia severity and total ADAS-Noncog
score was found. Thus, according to our results, non-
cognitive symptoms might occur at any stage of AD and
do not necessarily increase with dementia severity.
Among behavioural symptoms, appetite disturbances
and lack of cooperation showed the highest correlations,
whereas a tendency was observed for concentration
alterations. The rest of behavioural symptoms alone do
not show significant correlations, so they have similar
prevalence at any stage of disease. The relationship
between cognitive impairment degree and BPSD is con-
troversial, so that several studies supported it [43,57],
while others do not [58]. Discordances in BPSD preva-
lence reported by different studies are probably due to
the different scales used, as well as to cultural differ-
ences [59].
Regarding therapy, first choice treatments among
patients with mild to moderate stages of the disease
were administered rivastigmine and donepezil, whereas
memantine was predominant in patients with severe
dementia. The most used neuroleptic agent was risperi-
done. These data are similar to those provided by a
recent study [60] which analyzed the use of psychoana-
leptic drugs in our environment.
According to the data obtained in principal compo-
nent analisys using the criterion of eigenvalues >1, it is
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activity, psychosis and affective dimension) in both, the
higher and the lower, BPSD populations. Besides,
patients with higher BPSD scores show a new subsyn-
drome, represented by the lack of concentration or
cooperation. To the best of our knowledge, this new
subsyndrome have been not previously described, and
could be identified as an “inattentional syndrome” char-
acterized by the loss of patience, the frustration, and the
lack of cooperation induced by deficient attention. The
present study also provides an additional evidence for
t h ep r e s e n c eo fn e u r o p s y c h i a t r i cs u b s y n d r o m e si n
dementia, which were previously reported by studies
using the NPI [61].
The present study shows some limitations that should
be addressed. First of all, the patients sampled may suf-
fer from more behavioural disturbances than the average
population because the study was conducted in outpati-
ent clinics. Second, the previous use of antidementia
and psychotropic agents in our sample could affect the
frequency, severity, and total scores of BPSD. Finally,
the lack of correction for multiple testing is also a lim-
itation of our study.
The frequency of hallucinations in our study is around
30%, a percentage somewhat higher than that reported
with the NPI in both epidemiological [15,36] and clinical
populations [18,19]. Although this figure only indicates
the presence of hallucinations in the last year, it does
raise the possibility that there may have been a number
of patients with DLB in our study population, particu-
larly since many DLB patients could meet DSM-IV cri-
teria for AD. Then, the exclusive use of DSM-IV criteria
should also be adressed as a limitation.
From a qualitative perspective, the present results
should be similar to those obtained in other studies in
which different evaluation tools are used. In fact,
although other tools [19,55] probably assess noncogni-
tive symptoms in greater detail, ADAS-Noncog scale
include the main behavioural symptoms for assess
dementia. Nonetheless, ADAS-Noncog scale has the
limitation of being scored by the examiner based upon
patient and caregiver interview, and examiner impres-
sion. Consequently, the examiner might be overly influ-
enced by his/her snapshot impression of the patient at
the time of the visit, which may not be representative of
patient’s behaviours during typical daily routines.
In conclusion, the present work has several implica-
tions for the treatment of AD. The high prevalence of
BPSD in patients suffering from AD implies that the
assessment of behavioural symptoms is of great impor-
tance in clinical practice. In this regard, the use of scales
such as ADAS-Noncog, which provide information from
the patient and/or the caregiver in a short period of
time, is recommendable in outpatient clinics.
BPSD are often a manifestation of cognitive decline
and constitute one of the most common causes of
family burden and patient institutionalization. The
proper management of these symptoms will therefore
increase their wellbeing and quality of life [62].
Conclusions
T h ep r e s e n ts t u d ys h o w sah i g hp r e v a l e n c eo fB P S Di n
AD, since almost all patients (92%) showed some mood
or behavioural symptom at the time of exploration. The
most important frequent symptoms were lack of con-
centration (56%), tremors (56%), depression (44%), lack
of cooperation (36%), delusions (32%), tearfulness (28%),
and increased motor activity (29%). An “inattentional
syndrome” was also identified in patients with the
higher BPSD scores. Besides, a low correlation between
the severity of cognitive impairment and the behavioural
disturbances has been found. A total of 68% of physi-
cians were willing to use the ADAS-Noncog scale in the
future.
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